Researchers from Wayne State University Report Recent Findings in Small Interference RNAs (siRNAs) [Poly(amidoamine) Dendrimer Nanocarriers and Their Aerosol Formulations for siRNA Delivery to the Lung Epithelium]
By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Small Interference RNAs (siRNAs) have been published. According to news reporting out of Detroit, Michigan, by NewsRx editors, research stated, "Small interfering RNA (siRNA)-based therapies have great promise in the treatment of a number of prevalent pulmonary disorders including lung cancer, asthma and cystic fibrosis. However, progress in this area has been hindered due to the lack of carriers that can efficiently deliver siRNA to lung epithelial cells, and also due to challenges in developing oral inhalation (OI) formulations for the regional administration of siRNA and their carriers to the lungs."
Our news journalists obtained a quote from the research from Wayne State University, "In this work we report the ability of generation four, amine-terminated poly(amidoamine) (PAMAM) dendrimer (G4NH2)-siRNA complexes (dendriplexes) to silence the enhanced green fluorescent protein (eGFP) gene on A549 lung alveolar epithelial cells stably expressing eGFP. We also report the formulation of the dendriplexes and their aerosol characteristics in propellant-based portable OI devices. The size and gene silencing ability of the dendriplexes was seen not to be a strong function of the N/P ratio. Silencing efficiencies of up to 40% are reported. Stable dispersions of the dendriplexes encapsulated in mannitol and also in a biodegradable and water-soluble co-oligomer were prepared in hydrofluoroalkane (HFA)-based pressurized metered-dose inhalers (pMDIs). Their aerosol characteristics were very favorable, and conducive to deep lung deposition, with respirable fractions of up to 77%. Importantly, siRNA formulated as dendriplexes in pMDIs was shown to keep its integrity after the particle preparation processes, and also after long-term exposures to HFA. The relevance of this study stems from the fact that this is the first work to report the formulation of inhalable siRNA with aerosol properties suitable to deep lung deposition using pMDIs devices that are the least expensive and most widely used portable inhalers."
According to the news editors, the research concluded: "This study is relevant because, also for the first time, it shows that siRNA-G4NH2 dendriplexes can efficiently target lung alveolar epithelial A549 cells and silence genes even after siRNA has been exposed to the propellant environment."
For more information on this research see: Poly(amidoamine) Dendrimer Nanocarriers and Their Aerosol Formulations for siRNA Delivery to the Lung Epithelium. Molecular Pharmaceutics, 2014;11(6):1808-1822. Molecular Pharmaceutics can be contacted at: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA. (American Chemical Society - www.acs.org; Molecular Pharmaceutics - www.pubs.acs.org/journal/mpohbp)
Our news journalists report that additional information may be obtained by contacting D.S. Conti, Wayne State University, Dept. of Chem Engn & Mat Sci, Coll Engn, Detroit, MI 48202, United States. Additional authors for this research include D. Brewer, J. Grashik, S. Avasarala and S.R.P. da Rocha (see also Small Interference RNAs (siRNAs)).
Keywords for this news article include: Detroit, Michigan, Genetics, United States, North and Central America, Small Interference RNAs (siRNAs)
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC